Smallcap Sweep. 01-Mar-22
Toppling on unsteady updates
FD Technologies (FDP) partnership agreement with Microsoft to expand the reach of its KX Insights streaming data analytics platform. Also "KX intends to work with Microsoft to develop applications and services, leveraging [natch'] KX's capabilities as the world's fastest time-series database as a core building block." [SP=1518 Cap=422m]
essensys (ESYS) guides FY(July) trading below market expectations. Blames COVID related uncertainty. H1 rev up 3%. The pipeline for FY23 and FY24 is strong. [SP=240 Cap=155m]
Advanced Oncotherapy (AVO) re: approval of the LIGHT system at Daresbury. Regulatory agencies ask for "additional specific beam measurement data to document and confirm that performance can be maintained within the required tolerances for particular clinical applications". Now expects fully operational LIGHT system at 230 MeV during summer. [SP=24 Cap=109m]
Braemar Shipping Services (BMS) Disposal of Cory Brothers. Sounds like a Mafia hit but co has completed sales of its Logistics Division for a total of between £10.25m and £15.5m spread over three earnout periods to Dec 2024. [SP=238 Cap=77m]
Calnex Solutions (CLX) guides FY 22 in line, FY23 rev and op profit materially ahead of market expectations due to record order book. [SP=119.45 Cap=105m]
Oncimmune (ONC) Synexa Life Sciences has selected Oncimmune's ImmunoINSIGHTS platform to provide its clients access to specialist autoantibody services. [SP=124.28 Cap=86m]
AFC Energy (AFC) will field deploy its first Hybrid Fuel Cell system in Spain with partner, ACCIONA. It's part of ACCIONA's commitment to decarbonise its global portfolio of construction sites. AFC is building the first HFC system for the project. [SP=36.6 Cap=269m]
7digital (7DIG) €2.2m 3 yr contract expansion with un-named client. [SP=0.38 Cap=10m]
Softline (SFTL) current sanctions list represents less than 10% of turnover in Russia. Co has no material operations in Ukraine. [SP=NA Cap=NA]
GETECH (GTC) contract wins worth £1.2m. Includes annual and multi-year licences. [SP=27 Cap=18m]
Mobile Streams (MOS) monthly rev over $150k, up 88% since Dec update. [SP=0.4 Cap=10m]
DeepMatter (DMTR) 3 yr licensing and collaboration agreement with Standigm, a leading workflow AI drug discovery company. Initially worth £233k. [SP=0.24 Cap=9m]
Cellular Goods (CBX) launches Rejuvenating Cannabinoid Face Serum. Claims to prevent the signs of ageing caused by UV-light exposure and inflammation. Only £99 at Amazon and all good purveyors of miracles and potions. [SP=4.35 Cap=22m]
Volvere (VLE) guides FY(Dec) NAV 1353p (1365p). Pretax £0.07m (-£0.55m). Outlook "challenges experienced in 2021 in relation to cost increases and labour availability continue in 2022 but we are working hard to protect margins and retain staff, whilst seeking growth opportunities in food manufacturing". [SP=1135 Cap=29m]
Journeo (JNEO) £2.1m order from Edinburgh council to upgrade its real-time outdoor passenger display systems. [SP=100 Cap=9m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Got a credit card? use our Credit Card & Finance Calculators
Thanks to eyeball08,Wondergirly,bofh,johnstevens77,Bhoddhisatva, for Donating to support the site
MrC's Smallcap Sweeps for Mar 2022
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 02-Mar-22
Knocking out nonsense before it gets its boots on
Abingdon Health (ABDX) guides H1(Dec) rev £1.7m (£7.7m) down mailnly due to Gov't covid test fiasco. Judicial review of Gov't dispute in May. Co will "increasingly focus on the longer-term opportunities across multiple sectors, including infectious diseases, for lateral flow testing". Lots more on moves to crawl out of the hole. [SP=11.23 Cap=14m]
Alina (ALNA) Trading statement from the ego of Duncan Soukup who begins with the bizzare "I am pleased not to mention, relieved, to present the market with the following positive Trading Update:" Comma in the wrong place mate. Has sold Westcliff property. He thinks remaining property portfolio worth more than what the foolish valuers have assigned. "Hedging efforts have resulted in significant positive contribution during the recent and on-going market correction." [SP=16 Cap=4m]
Diurnal (DNL) FDA requires protocol modification for Phase 1 of trial treatment of male hypogonadism, primarily relating to additional clinical safety data from the two lowest dose groups. [SP=51 Cap=86m]
Eden Research (EDEN) guides FY(Dec) rev flat at £1.4m (up 6% in €) with an op loss of c.£3.4m (£2.2m). "Significant expansion of the Company's addressable market was achieved as the labels for both Mevalone and Cedroz were expanded with the addition of new countries, disease and crop targets." So where's the growth? Lots of hope though. [SP=6.88 Cap=26m]
CMC Market (CMCX) will repurchase shares up to £30m (c. 5% of cap). [SP=228 Cap=664m]
Global Ports (GPH) new auditor. Will state reason for KPMG's resignation in a letter to every person entitled to receive a copy of the accounts. Why not just say now? False mkt? [SP=115 Cap=72m]
Byotrol (BYOT) now expects FY(Mar) product sales £5.2m, down yoy but flat on FY20. Is that a warning? Not clear. FY total rev "very much dependent on exactly which IP agreements we are able (and - dependent on terms - willing) to close in the next four weeks. If we do not conclude any large IP sales, we would expect overall revenues to be no less than £6m, with positive underlying EBITDA for the year." [SP=2.72 Cap=12m]
Stagecoach (SGC) guides FY(Apr) in line. Welcomes yesterday's Gov't announcement of further recovery funding for the continuation of regional bus services in England, Warns of "continuing forecasting uncertainty in relation to passenger demand, payments from government to support the continuation of regional bus services during that recovery phase, and cost inflation". [SP=85.53 Cap=471m]
Vertu Motors (VTU) £5m hike in FY(Feb) guidance of adj pretax to £75m+. Another share buyback of £3m. Co "considers that scale is a vital success factor in the sector given the need for strong brands and investment in digital developments and continues to have ambitious growth aspirations for the Group in the next few years". Guides FY23 some way below FY22 but well ahead of periods prior to FY22. [SP=57.6 Cap=207m]
GYG (GYG) guides FY(Dec) rev €62.8m (€58.9m). Adj EBITA in line. "Outlook for the Group is encouraging for 2022, albeit future changes in lockdowns and travel restrictions as well as the wider geo-political environment may affect the full year performance." [SP=46.55 Cap=22m]
Osirium Technologies (OSI) new customer wins. YTD bookings ahead of the same period last year. Co is seeing particular opportunities with NHS trusts. [SP=4.63 Cap=2m]
Norman Broadbent (NBB) guides FY(Dec) Net Fee Income down 5% but Q4 showed a very positive recovery. Gross margin 89% (79%). EBITDA breakeven, before exceptional restructuring costs. Chmn trills ""I am incredibly pleased that we are ahead of our strategic turnaround plan and that the business has continued to trade strongly after an excellent fourth quarter". [SP=7.51 Cap=5m]
Safestay (SSTY) end sale process. Shareholders rejected an indicative offer. Trading in line. [SP=17.25 Cap=12m]
In line: ETP
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Knocking out nonsense before it gets its boots on
Abingdon Health (ABDX) guides H1(Dec) rev £1.7m (£7.7m) down mailnly due to Gov't covid test fiasco. Judicial review of Gov't dispute in May. Co will "increasingly focus on the longer-term opportunities across multiple sectors, including infectious diseases, for lateral flow testing". Lots more on moves to crawl out of the hole. [SP=11.23 Cap=14m]
Alina (ALNA) Trading statement from the ego of Duncan Soukup who begins with the bizzare "I am pleased not to mention, relieved, to present the market with the following positive Trading Update:" Comma in the wrong place mate. Has sold Westcliff property. He thinks remaining property portfolio worth more than what the foolish valuers have assigned. "Hedging efforts have resulted in significant positive contribution during the recent and on-going market correction." [SP=16 Cap=4m]
Diurnal (DNL) FDA requires protocol modification for Phase 1 of trial treatment of male hypogonadism, primarily relating to additional clinical safety data from the two lowest dose groups. [SP=51 Cap=86m]
Eden Research (EDEN) guides FY(Dec) rev flat at £1.4m (up 6% in €) with an op loss of c.£3.4m (£2.2m). "Significant expansion of the Company's addressable market was achieved as the labels for both Mevalone and Cedroz were expanded with the addition of new countries, disease and crop targets." So where's the growth? Lots of hope though. [SP=6.88 Cap=26m]
CMC Market (CMCX) will repurchase shares up to £30m (c. 5% of cap). [SP=228 Cap=664m]
Global Ports (GPH) new auditor. Will state reason for KPMG's resignation in a letter to every person entitled to receive a copy of the accounts. Why not just say now? False mkt? [SP=115 Cap=72m]
Byotrol (BYOT) now expects FY(Mar) product sales £5.2m, down yoy but flat on FY20. Is that a warning? Not clear. FY total rev "very much dependent on exactly which IP agreements we are able (and - dependent on terms - willing) to close in the next four weeks. If we do not conclude any large IP sales, we would expect overall revenues to be no less than £6m, with positive underlying EBITDA for the year." [SP=2.72 Cap=12m]
Stagecoach (SGC) guides FY(Apr) in line. Welcomes yesterday's Gov't announcement of further recovery funding for the continuation of regional bus services in England, Warns of "continuing forecasting uncertainty in relation to passenger demand, payments from government to support the continuation of regional bus services during that recovery phase, and cost inflation". [SP=85.53 Cap=471m]
Vertu Motors (VTU) £5m hike in FY(Feb) guidance of adj pretax to £75m+. Another share buyback of £3m. Co "considers that scale is a vital success factor in the sector given the need for strong brands and investment in digital developments and continues to have ambitious growth aspirations for the Group in the next few years". Guides FY23 some way below FY22 but well ahead of periods prior to FY22. [SP=57.6 Cap=207m]
GYG (GYG) guides FY(Dec) rev €62.8m (€58.9m). Adj EBITA in line. "Outlook for the Group is encouraging for 2022, albeit future changes in lockdowns and travel restrictions as well as the wider geo-political environment may affect the full year performance." [SP=46.55 Cap=22m]
Osirium Technologies (OSI) new customer wins. YTD bookings ahead of the same period last year. Co is seeing particular opportunities with NHS trusts. [SP=4.63 Cap=2m]
Norman Broadbent (NBB) guides FY(Dec) Net Fee Income down 5% but Q4 showed a very positive recovery. Gross margin 89% (79%). EBITDA breakeven, before exceptional restructuring costs. Chmn trills ""I am incredibly pleased that we are ahead of our strategic turnaround plan and that the business has continued to trade strongly after an excellent fourth quarter". [SP=7.51 Cap=5m]
Safestay (SSTY) end sale process. Shareholders rejected an indicative offer. Trading in line. [SP=17.25 Cap=12m]
In line: ETP
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 03-Mar-22
A stent for the sclerotic vein of insight
Zytronic (ZYT) AGM stmt: "The first five months of this financial year have seen a continuing and significant improvement." Rev up 25%. Order book up 45%, partly benefitting from some advance orders. [SP=152.6 Cap=17m]
1Spatial (SPA) guides FY(Jan) rev over £26.4m (£24.6m) with double digit growth in recurring revenue. Adj EBITDA £3.8m (£3.6m) in line with expectations. [SP=42.26 Cap=47m]
Synairgen (SNG) US asks co "to temporarily pause activities to prepare clinical supplies for ACTIV-2 Phase 3 until the timeline for the activation of this agent in the trial is clarified. Synairgen continues to await the Phase 2 data from the US NIH ACTIV-2 trial". Also in vitro studies show "SNG001 has potent antiviral activity against SARS-CoV-2 Delta and Omicron variants at concentrations that are readily achievable following inhaled delivery of interferon beta". [SP=18.5 Cap=37m]
Morses Club (MCL) trading strong in FY(Feb). Folds U Account product due to significant changes in market conditions. [SP=12.73 Cap=17m]
N Brown (BWNG) guides FY(Feb) in line but warns FY23 adj EBITDA similar to FY21 before growing again. Blames inflation. [SP=36.96 Cap=170m]
Palace Capital (PCA) exceeds disposal strategy targets with sale of Pelham House, Brighton, for £1.6m. [SP=240 Cap=111m]
Gelion (GELN) CEO scarpers. He is thanked. [SP=107 Cap=115m]
M&C Saatchi (SAA) PUSU extended to 31 March. [SP=176 Cap=215m]
SimiGon (SIM) Israel cancelled the ex parte restraining order to prevent delisting. Will be a hearing on March 10. Co makes urrently no change to the expected timetable for the merger and Cancellation. [SP=4 Cap=2m]
De La Rue (DLAR) pension scheme deficit (AT Apr 21) down to £120m (£177m) after actuarial valuation. Deficit contributions will remain at £15m PA to 2029. Was planned to go to £24.5m PA. [SP=110 Cap=215m]
Next Fifteen (NFC) £50m placing [yest] at 1110p, a 4.3% discount, to part-fund the acquisition of Engine Acquisition. [SP=1116 Cap=1036m]
Empiric Student Property (ESP) FY(Dec). Booking at 2 Mar broadly in line with our pre-Covid bookings. 2022/23 academic year occupancy target 85% to 95%, expect to be towards the top of this. Plans 2.5p minimum div. [SP=88.6 Cap=534m]
In line: UBG
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
A stent for the sclerotic vein of insight
Zytronic (ZYT) AGM stmt: "The first five months of this financial year have seen a continuing and significant improvement." Rev up 25%. Order book up 45%, partly benefitting from some advance orders. [SP=152.6 Cap=17m]
1Spatial (SPA) guides FY(Jan) rev over £26.4m (£24.6m) with double digit growth in recurring revenue. Adj EBITDA £3.8m (£3.6m) in line with expectations. [SP=42.26 Cap=47m]
Synairgen (SNG) US asks co "to temporarily pause activities to prepare clinical supplies for ACTIV-2 Phase 3 until the timeline for the activation of this agent in the trial is clarified. Synairgen continues to await the Phase 2 data from the US NIH ACTIV-2 trial". Also in vitro studies show "SNG001 has potent antiviral activity against SARS-CoV-2 Delta and Omicron variants at concentrations that are readily achievable following inhaled delivery of interferon beta". [SP=18.5 Cap=37m]
Morses Club (MCL) trading strong in FY(Feb). Folds U Account product due to significant changes in market conditions. [SP=12.73 Cap=17m]
N Brown (BWNG) guides FY(Feb) in line but warns FY23 adj EBITDA similar to FY21 before growing again. Blames inflation. [SP=36.96 Cap=170m]
Palace Capital (PCA) exceeds disposal strategy targets with sale of Pelham House, Brighton, for £1.6m. [SP=240 Cap=111m]
Gelion (GELN) CEO scarpers. He is thanked. [SP=107 Cap=115m]
M&C Saatchi (SAA) PUSU extended to 31 March. [SP=176 Cap=215m]
SimiGon (SIM) Israel cancelled the ex parte restraining order to prevent delisting. Will be a hearing on March 10. Co makes urrently no change to the expected timetable for the merger and Cancellation. [SP=4 Cap=2m]
De La Rue (DLAR) pension scheme deficit (AT Apr 21) down to £120m (£177m) after actuarial valuation. Deficit contributions will remain at £15m PA to 2029. Was planned to go to £24.5m PA. [SP=110 Cap=215m]
Next Fifteen (NFC) £50m placing [yest] at 1110p, a 4.3% discount, to part-fund the acquisition of Engine Acquisition. [SP=1116 Cap=1036m]
Empiric Student Property (ESP) FY(Dec). Booking at 2 Mar broadly in line with our pre-Covid bookings. 2022/23 academic year occupancy target 85% to 95%, expect to be towards the top of this. Plans 2.5p minimum div. [SP=88.6 Cap=534m]
In line: UBG
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 04-Mar-22
Pulling down the trousers of twaddle
Malvern (MLVN) guides FY(Dec) rev £2.4m up 26% and lossc.£1m (loss £1.33m). Net debt £5.8m. Debt facility renegotiated. January pathway intake was 80 students (43). "Our pipeline of bookings for our ELT centres in London and Manchester are the strongest since the start of the pandemic and our expectation is to return to 2019 levels." [SP=0.12 Cap=3m]
Supply @ME Capital (SYME). Chmn scarpers for personal reasons. Four months is enough I guess. Appoints advisor for strategic review "as it prepares for the next phase of growth". Irony. Nice. [SP=0.09 Cap=37m]
Ten Lifestyle (TENG) guides FY(Feb) rev in line but adj EBITDA below expectations due to hiring more staff in the autumn, but omicrom hit member requests. Started to see an increase in activity again in Feb in EMEA region. Guides FY23 in line. [SP=107 Cap=90m]
Accsys Technologies (AXS) guides FY22 EBITDA around lower end of "market consensus expectations". Consensus is a single figure, so it can't be. Blames temporary production downtime at the Arnhem plant primarily due to the installation of the new fourth reactor and maintenance work. Also final investment decision to construct and operate a new USA Accoya factory. All key commercial agreements, including bank loans of US$80m, are now in place. [SP=144.5 Cap=277m]
DP Eurasia (DPEU) too early to quantify any possible ramifications of the war for the Russian business. Co continues to perform ahead of pre-Covid levels. [SP=46 Cap=66m]
Oncimmune (ONC) commercial contract with a new top 10 global pharma co, initially focusing on the autoantibody profiling of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. No £££. [SP=133.32 Cap=92m]
MITIE (MTO) CMA has launched an investigation into the participation by Mitie in the "on-going procurement processes run by the Home Office for the contracts to supply certain services at Heathrow and Derwentside Immigration Removal Centre". Mitie is confident that it has no case to answer. [SP=53 Cap=758m]
Verici Dx (VRCI) £10m (min) placing at 35p, a 7% discount, to keep going. [SP=37.89 Cap=53m]
Chill Brands (CHLL) previously announced additional orders valued at approximately $1m may not all be booked by YE(Mar). Blames logistics and 'geopolitical issues'. Confident that any remaining orders will be placed in H1. Co seeking to onshore manufacturing via establishment of a North American strategic partnership. Awarding a manufacturing contract is not a 'strategic partnership'. [SP=7.53 Cap=17m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Pulling down the trousers of twaddle
Malvern (MLVN) guides FY(Dec) rev £2.4m up 26% and lossc.£1m (loss £1.33m). Net debt £5.8m. Debt facility renegotiated. January pathway intake was 80 students (43). "Our pipeline of bookings for our ELT centres in London and Manchester are the strongest since the start of the pandemic and our expectation is to return to 2019 levels." [SP=0.12 Cap=3m]
Supply @ME Capital (SYME). Chmn scarpers for personal reasons. Four months is enough I guess. Appoints advisor for strategic review "as it prepares for the next phase of growth". Irony. Nice. [SP=0.09 Cap=37m]
Ten Lifestyle (TENG) guides FY(Feb) rev in line but adj EBITDA below expectations due to hiring more staff in the autumn, but omicrom hit member requests. Started to see an increase in activity again in Feb in EMEA region. Guides FY23 in line. [SP=107 Cap=90m]
Accsys Technologies (AXS) guides FY22 EBITDA around lower end of "market consensus expectations". Consensus is a single figure, so it can't be. Blames temporary production downtime at the Arnhem plant primarily due to the installation of the new fourth reactor and maintenance work. Also final investment decision to construct and operate a new USA Accoya factory. All key commercial agreements, including bank loans of US$80m, are now in place. [SP=144.5 Cap=277m]
DP Eurasia (DPEU) too early to quantify any possible ramifications of the war for the Russian business. Co continues to perform ahead of pre-Covid levels. [SP=46 Cap=66m]
Oncimmune (ONC) commercial contract with a new top 10 global pharma co, initially focusing on the autoantibody profiling of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. No £££. [SP=133.32 Cap=92m]
MITIE (MTO) CMA has launched an investigation into the participation by Mitie in the "on-going procurement processes run by the Home Office for the contracts to supply certain services at Heathrow and Derwentside Immigration Removal Centre". Mitie is confident that it has no case to answer. [SP=53 Cap=758m]
Verici Dx (VRCI) £10m (min) placing at 35p, a 7% discount, to keep going. [SP=37.89 Cap=53m]
Chill Brands (CHLL) previously announced additional orders valued at approximately $1m may not all be booked by YE(Mar). Blames logistics and 'geopolitical issues'. Confident that any remaining orders will be placed in H1. Co seeking to onshore manufacturing via establishment of a North American strategic partnership. Awarding a manufacturing contract is not a 'strategic partnership'. [SP=7.53 Cap=17m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 07-Mar-22
Rash rendering of releases
MTI Wireless Edge (MWE) FY(Dec) in line. FY22 started well, Will exit Russia (6% of rev). [SP=46 Cap=41m]
Amigo (AMGO) FCA says co could return to lending subject to conditions. Would be limited in volume and for co to demonstrate that it was lending in a way that meets the FCA's expectations. [SP=2.75 Cap=13m]
600 (SIXH) sells Machine Tool Solutions div for $21m; will complete the shift of strategy towards its growing industrial laser systems business. [SP=11.25 Cap=14m]
Cindrigo (CINH) proposed waste to energy project in Kiev . Still suspended.has been suspended. [SP=0.12 Cap=NA]
Zoo Digital (ZOO) launches Korean hub to address growing demand for regional content. [SP=98 Cap=88m]
Plexus (POS) suspend activities with Russian co Gusar. No material impact on trading. [SP=5.5 Cap=6m]
Cloudcoco (CLCO) FY(Sept) looks in line. Strong start to current year. Significant upside from the acquisitions expected. [SP=1.63 Cap=12m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Rash rendering of releases
MTI Wireless Edge (MWE) FY(Dec) in line. FY22 started well, Will exit Russia (6% of rev). [SP=46 Cap=41m]
Amigo (AMGO) FCA says co could return to lending subject to conditions. Would be limited in volume and for co to demonstrate that it was lending in a way that meets the FCA's expectations. [SP=2.75 Cap=13m]
600 (SIXH) sells Machine Tool Solutions div for $21m; will complete the shift of strategy towards its growing industrial laser systems business. [SP=11.25 Cap=14m]
Cindrigo (CINH) proposed waste to energy project in Kiev . Still suspended.has been suspended. [SP=0.12 Cap=NA]
Zoo Digital (ZOO) launches Korean hub to address growing demand for regional content. [SP=98 Cap=88m]
Plexus (POS) suspend activities with Russian co Gusar. No material impact on trading. [SP=5.5 Cap=6m]
Cloudcoco (CLCO) FY(Sept) looks in line. Strong start to current year. Significant upside from the acquisitions expected. [SP=1.63 Cap=12m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 08-Mar-22
Oiled up and head down to wrestle the market
Ted Baker (TED) CFO scarpers. He is thanked. [SP=92 Cap=170m]
SourceBio (SBI) covid tests down to 1000/d from 2700/d in Jan. Buys LDPath, a London based leader in Digital Pathology testing services, for £18.5m plus earn out. Immediately earnings enhancing excluding transaction related costs. COnsidering share buy backo [SP=123.45 Cap=92m]
Tasty (TAST) guides FY(Dec) rev up 44% and down 22% on 2019 (from fewer sites now). Adj EBITDA1 c. £8m (£2.7m). Pre IFRS 16 adjusted EBITDA c. £3.9m (-£1.5m). "Well publicised industry employee shortages and supply issues are being managed and will continue to be a focus." [SP=4.88 Cap=7m]
J Menzies (MNZS) extends PUSU deadline. [SP=507.27 Cap=466m]
Foxtons (FOXT) Up to £3m buyback [SP=31.35 Cap=100m]
Tungsten (TUNG) extends PUSU deadline. [SP=32 Cap=40m]
NWF (NWF) guides FY(May) significantly ahead mgmt expectations. Effect of war and sanctions "To date, there have been no major supply issues ". [SP=209.55 Cap=103m]
ZAIM Credit Systems (ZAIM) re: situation in Russia. Co complying with all UK, US & EU sanctions. Zaim itself has no relationships with any Russian banks. Accelerating its work to expand into other European countries. Zaim Express operates solely within Russia and therefore is not affected by international restrictions on using the SWIFT international payment system. [SP=2 Cap=9m]
Made.com (MADE) FY(Dec). Warns of soft FY22, "no longer anticipating any tailwind from the market".Guides rev up 25-35%, adj EBITDA £5-15m. [SP=71.4 Cap=280m]
Synectics (SNX) 5 yr contract from National Grid for security management software support. Worth c.£600k this FY but lesser amounts in each of the remaining years. Total is confidential. [SP=109.55 Cap=19m]
IXICO (IXI) 5 yr contract for Huntington's disease trial worth c. £800k. [SP=42.02 Cap=20m]
Revolution Bars Group (RBG) FRC issues severe reprimands and fines to KPMG and an audit partner for historic audit failings in FY15 following RBG's IPO. "The failings relate to three specific areas of the Audits: supplier rebates and listing fees; share-based payments; and (for FY2016 only) deferred taxation. The Company's financial statements for FY2015 and FY2016 contained various misstatements which had to be corrected, some of which arose from the three areas mentioned, and some of which were material to the financial statements as a whole." [SP=18.33 Cap=42m]
In line: ORPH, HAT, RWA
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Oiled up and head down to wrestle the market
Ted Baker (TED) CFO scarpers. He is thanked. [SP=92 Cap=170m]
SourceBio (SBI) covid tests down to 1000/d from 2700/d in Jan. Buys LDPath, a London based leader in Digital Pathology testing services, for £18.5m plus earn out. Immediately earnings enhancing excluding transaction related costs. COnsidering share buy backo [SP=123.45 Cap=92m]
Tasty (TAST) guides FY(Dec) rev up 44% and down 22% on 2019 (from fewer sites now). Adj EBITDA1 c. £8m (£2.7m). Pre IFRS 16 adjusted EBITDA c. £3.9m (-£1.5m). "Well publicised industry employee shortages and supply issues are being managed and will continue to be a focus." [SP=4.88 Cap=7m]
J Menzies (MNZS) extends PUSU deadline. [SP=507.27 Cap=466m]
Foxtons (FOXT) Up to £3m buyback [SP=31.35 Cap=100m]
Tungsten (TUNG) extends PUSU deadline. [SP=32 Cap=40m]
NWF (NWF) guides FY(May) significantly ahead mgmt expectations. Effect of war and sanctions "To date, there have been no major supply issues ". [SP=209.55 Cap=103m]
ZAIM Credit Systems (ZAIM) re: situation in Russia. Co complying with all UK, US & EU sanctions. Zaim itself has no relationships with any Russian banks. Accelerating its work to expand into other European countries. Zaim Express operates solely within Russia and therefore is not affected by international restrictions on using the SWIFT international payment system. [SP=2 Cap=9m]
Made.com (MADE) FY(Dec). Warns of soft FY22, "no longer anticipating any tailwind from the market".Guides rev up 25-35%, adj EBITDA £5-15m. [SP=71.4 Cap=280m]
Synectics (SNX) 5 yr contract from National Grid for security management software support. Worth c.£600k this FY but lesser amounts in each of the remaining years. Total is confidential. [SP=109.55 Cap=19m]
IXICO (IXI) 5 yr contract for Huntington's disease trial worth c. £800k. [SP=42.02 Cap=20m]
Revolution Bars Group (RBG) FRC issues severe reprimands and fines to KPMG and an audit partner for historic audit failings in FY15 following RBG's IPO. "The failings relate to three specific areas of the Audits: supplier rebates and listing fees; share-based payments; and (for FY2016 only) deferred taxation. The Company's financial statements for FY2015 and FY2016 contained various misstatements which had to be corrected, some of which arose from the three areas mentioned, and some of which were material to the financial statements as a whole." [SP=18.33 Cap=42m]
In line: ORPH, HAT, RWA
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 09-Mar-22
A cold shower of smallcap smatterings
STV (STV) buys minority stake in Mighty Productions. Option to increase. Mighty produces The Weakest Link, !mpossible and Tipping Point. [SP=NA Cap=NA]
Mothercare (MTC) Russian local partner pausing operations in c.120 stores and online. Russia is c. 20-25% of Mothercare's rev and was expected to contribute c. £0.5m per month profit. [SP=13.95 Cap=79m]
Gfinity (GFIN) guides FY(June) below market expectations. Blames slower than expected return to live esports events and delay to betting partnership. H1 rev up 8%. [SP=2.4 Cap=26m]
Photo-Me (PHTM) the unrecommended mandatory offer has lapsed. [SP=68.2 Cap=258m]
Taylor Maritime Investments (TMIP) sells 2 ships for $33.3m. Represents IRRs over 100% and a MOIC (?) of 1.4x and 1.7x respectively. A Handysize is stuck in the Black sea. Crew evacuated. Co estimates port calls to Ukraine and Russia were under 2% and 3% respectively of total port calls by TMI vessels. "TMI expects that international trade patterns will adapt as demand needs to be satisfied from other sources; as current buyers of Black Sea grain potentially look to North and South America as a substitute, a greater proportion of Black Sea grain will be picked up by China." [SP=95 Cap=416m]
Renalytix (RENX) launches new provider access portal, myIntelX, "which will provide nationwide online access for physicians to order KidneyIntelX bioprognosticT testing". [SP=283 Cap=271m]
Fox Marble (FOX) €200k order, will be booked this FY. Also non-binding agreement to supply Unik Construction with up to 30,000m2 of material starting Q2. [SP=1.03 Cap=4m]
Tissue Regenix (TRX) exclusive distribution agreement with Geistlich for the distribution of OrthoPure XT in Italy. Potential for extension to wider geographies. [SP=0.35 Cap=24m]
Headlam (HEAD) FY(Dec) in line and current trading in line. £30m cap return via special div and buyback. [SP=345 Cap=294m]
Somero (SOM) FY(Dec) in line. Guides modest growth in FY22. [SP=430 Cap=241m]
Stagecoach (SGC) 105p rec offer, a 37% premium. [SP=77.1 Cap=425m]
Gaming Realms (GMR) trading ahead of mgmt expectations. Wins iGaming Supplier license to supply games in Ontario ahead of the opening of regulated iGaming market on 4 April. Population 15m, larger than any State within the U.S. that is currently licensed for iGaming. [SP=23 Cap=67m]
In line: TTG
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
A cold shower of smallcap smatterings
STV (STV) buys minority stake in Mighty Productions. Option to increase. Mighty produces The Weakest Link, !mpossible and Tipping Point. [SP=NA Cap=NA]
Mothercare (MTC) Russian local partner pausing operations in c.120 stores and online. Russia is c. 20-25% of Mothercare's rev and was expected to contribute c. £0.5m per month profit. [SP=13.95 Cap=79m]
Gfinity (GFIN) guides FY(June) below market expectations. Blames slower than expected return to live esports events and delay to betting partnership. H1 rev up 8%. [SP=2.4 Cap=26m]
Photo-Me (PHTM) the unrecommended mandatory offer has lapsed. [SP=68.2 Cap=258m]
Taylor Maritime Investments (TMIP) sells 2 ships for $33.3m. Represents IRRs over 100% and a MOIC (?) of 1.4x and 1.7x respectively. A Handysize is stuck in the Black sea. Crew evacuated. Co estimates port calls to Ukraine and Russia were under 2% and 3% respectively of total port calls by TMI vessels. "TMI expects that international trade patterns will adapt as demand needs to be satisfied from other sources; as current buyers of Black Sea grain potentially look to North and South America as a substitute, a greater proportion of Black Sea grain will be picked up by China." [SP=95 Cap=416m]
Renalytix (RENX) launches new provider access portal, myIntelX, "which will provide nationwide online access for physicians to order KidneyIntelX bioprognosticT testing". [SP=283 Cap=271m]
Fox Marble (FOX) €200k order, will be booked this FY. Also non-binding agreement to supply Unik Construction with up to 30,000m2 of material starting Q2. [SP=1.03 Cap=4m]
Tissue Regenix (TRX) exclusive distribution agreement with Geistlich for the distribution of OrthoPure XT in Italy. Potential for extension to wider geographies. [SP=0.35 Cap=24m]
Headlam (HEAD) FY(Dec) in line and current trading in line. £30m cap return via special div and buyback. [SP=345 Cap=294m]
Somero (SOM) FY(Dec) in line. Guides modest growth in FY22. [SP=430 Cap=241m]
Stagecoach (SGC) 105p rec offer, a 37% premium. [SP=77.1 Cap=425m]
Gaming Realms (GMR) trading ahead of mgmt expectations. Wins iGaming Supplier license to supply games in Ontario ahead of the opening of regulated iGaming market on 4 April. Population 15m, larger than any State within the U.S. that is currently licensed for iGaming. [SP=23 Cap=67m]
In line: TTG
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 10-Mar-22
Taking down what's on the up
PipeHawk (PIP) contract with Ventive for second phase of the project to manufacture a 'ground breaking' product to provide domestic heating and hot water. Ventive to pay £1.1m and PIP £0.4m for project. Production of the "Ventive Home" System is expected to begin in June to deliver rev c.£7.5m in FY23. [SP=26.45 Cap=10m]
Dekel Agri-Vision (DKL) Crude Palm Oil high season now delayed to Apr from Feb. Other updates. [SP=6.19 Cap=33m]
finnCap (FCAP) YTD rev now above £45-£50m FY guidance. Further potential deals to close, [SP=26.75 Cap=48m]
boohoo (BOO) guides FY(Feb) in line. Higher returns rates expected to continue in the first half of FY23. Guides adj EBITDA in line at £125m. [SP=78.88 Cap=1000m]
Argo Blockchain (ARB) $26.66m secured loan at 8.25% to recapitalize the purchase of electrical infrastructure equipment at new Texas facility. [SP=64.5 Cap=302m]
Redx Pharma (REDX) study shows its novel anti-fibrotic drug candidate has excellent safety and pharmacokinetic profile. Plans Phase 2 this year. [SP=73 Cap=201m]
Northbridge Industrial Services (NBI) positive start to year has continued. Will resume divs with 1p final div. To change name to Crestchic following disposal of the Tasman division. [SP=165.5 Cap=48m]
Jarvis Securities (JIM) FY(Dec) rev up 7%. EPS 13.91 up 9%. Outlook: will benefit from higher int rates but "experiencing cost increases from many of our suppliers. Some of these have been passed onto our commercial customers, however we would prefer to offset these cost increases through continued growth in order to maintain our competitive pricing model." [SP=235 Cap=105m]
Purplebricks (PURP) CEO leaves end of the month due to personal circumstances. He is thanked. [SP=14.5 Cap=44m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Taking down what's on the up
PipeHawk (PIP) contract with Ventive for second phase of the project to manufacture a 'ground breaking' product to provide domestic heating and hot water. Ventive to pay £1.1m and PIP £0.4m for project. Production of the "Ventive Home" System is expected to begin in June to deliver rev c.£7.5m in FY23. [SP=26.45 Cap=10m]
Dekel Agri-Vision (DKL) Crude Palm Oil high season now delayed to Apr from Feb. Other updates. [SP=6.19 Cap=33m]
finnCap (FCAP) YTD rev now above £45-£50m FY guidance. Further potential deals to close, [SP=26.75 Cap=48m]
boohoo (BOO) guides FY(Feb) in line. Higher returns rates expected to continue in the first half of FY23. Guides adj EBITDA in line at £125m. [SP=78.88 Cap=1000m]
Argo Blockchain (ARB) $26.66m secured loan at 8.25% to recapitalize the purchase of electrical infrastructure equipment at new Texas facility. [SP=64.5 Cap=302m]
Redx Pharma (REDX) study shows its novel anti-fibrotic drug candidate has excellent safety and pharmacokinetic profile. Plans Phase 2 this year. [SP=73 Cap=201m]
Northbridge Industrial Services (NBI) positive start to year has continued. Will resume divs with 1p final div. To change name to Crestchic following disposal of the Tasman division. [SP=165.5 Cap=48m]
Jarvis Securities (JIM) FY(Dec) rev up 7%. EPS 13.91 up 9%. Outlook: will benefit from higher int rates but "experiencing cost increases from many of our suppliers. Some of these have been passed onto our commercial customers, however we would prefer to offset these cost increases through continued growth in order to maintain our competitive pricing model." [SP=235 Cap=105m]
Purplebricks (PURP) CEO leaves end of the month due to personal circumstances. He is thanked. [SP=14.5 Cap=44m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 11-Mar-22
Mrinformation or Misinformation?
GETECH (GTC) The Highland Council and GTC a vision to create a regional network of green hydrogen hubs across the Scottish Highlands. £100k from the council to cost of planning. [SP=29.01 Cap=19m]
MyCelx Technologies (MXY) $2.21m placing at 50p, a 5% discount, to accelerate the commercialisation of the Company's remediation system in the US [SP=NA Cap=NA]
Brickability (BRCK) JV for manufacture of clay roof tiles in Germany. Guides c.£9m PA rev for co. COst €0.5m and €3.5m loan. [SP=89 Cap=266m]
Deepverge (DVRG) Modern Water subsidiary gets production orders up 39% in Q1, worth c£5m. [SP=14.28 Cap=31m]
DP Eurasia (DPEU) reiterates no material disruption to Russian operation but will limit any further investment. Royalty payments suspended. [SP=43.7 Cap=64m]
Avast (AVST) pulls products from Russia and Belarus and suspends all marketing and sales operations.Ukraine, Russia and Belarus were 1.5% of rev. [SP=640.4 Cap=6659m]
Omega Diagnostics (ODX) application for approval of the professional-use PCR covid test in UK rejected. "Some supporting data provided by third-party development partners...used comparator PCR results from studies... which were not CE-marked and/or did not meet the sensitivity/specificity requirements." Sounds like co should have known all this. ODX does not plan to commission further studies due to insufficient demand. [SP=4.15 Cap=13m]
Hardide (HDD) guides H1 rev up over 40%. "Optimistic that the increasing demand from existing customers and the high-volume potential of a number of projects will result in the Group achieving its previous upward sales trajectory." Is that in line? [SP=30.95 Cap=17m]
Quantum Blockchain Technologies (QBT) board "extremely pleased with the results achieved to date" in its mining optimisation research. Exciting paragraphs follow. [SP=2.38 Cap=24m]
SRT Marine Systems (SRT) £4.9m placing at 30p, a nasty 25% discount, to enable implementation of multiple projects simultaneously within expected contractual timescales and to enable increased production of its digital navigation transceivers. No shares for us plebs this time. [SP=38 Cap=62m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Mrinformation or Misinformation?
GETECH (GTC) The Highland Council and GTC a vision to create a regional network of green hydrogen hubs across the Scottish Highlands. £100k from the council to cost of planning. [SP=29.01 Cap=19m]
MyCelx Technologies (MXY) $2.21m placing at 50p, a 5% discount, to accelerate the commercialisation of the Company's remediation system in the US [SP=NA Cap=NA]
Brickability (BRCK) JV for manufacture of clay roof tiles in Germany. Guides c.£9m PA rev for co. COst €0.5m and €3.5m loan. [SP=89 Cap=266m]
Deepverge (DVRG) Modern Water subsidiary gets production orders up 39% in Q1, worth c£5m. [SP=14.28 Cap=31m]
DP Eurasia (DPEU) reiterates no material disruption to Russian operation but will limit any further investment. Royalty payments suspended. [SP=43.7 Cap=64m]
Avast (AVST) pulls products from Russia and Belarus and suspends all marketing and sales operations.Ukraine, Russia and Belarus were 1.5% of rev. [SP=640.4 Cap=6659m]
Omega Diagnostics (ODX) application for approval of the professional-use PCR covid test in UK rejected. "Some supporting data provided by third-party development partners...used comparator PCR results from studies... which were not CE-marked and/or did not meet the sensitivity/specificity requirements." Sounds like co should have known all this. ODX does not plan to commission further studies due to insufficient demand. [SP=4.15 Cap=13m]
Hardide (HDD) guides H1 rev up over 40%. "Optimistic that the increasing demand from existing customers and the high-volume potential of a number of projects will result in the Group achieving its previous upward sales trajectory." Is that in line? [SP=30.95 Cap=17m]
Quantum Blockchain Technologies (QBT) board "extremely pleased with the results achieved to date" in its mining optimisation research. Exciting paragraphs follow. [SP=2.38 Cap=24m]
SRT Marine Systems (SRT) £4.9m placing at 30p, a nasty 25% discount, to enable implementation of multiple projects simultaneously within expected contractual timescales and to enable increased production of its digital navigation transceivers. No shares for us plebs this time. [SP=38 Cap=62m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 14-Mar-22
Rough & ready regulatory roundup
Cake Box (CBOX) Trading in line. CFO scarpers. He is thanked. [SP=200 Cap=80m]
Live Company (LVCG) £0.225m placing at 5p, a 2% premium, for a video production division, further expansion of the KPOP-FLEX concept and additional working capital. Over 18k tickets for KPOP.FLEX festival. [SP=4.9 Cap=8m]
EQTEC (EQT) collaboration agreement wityh SEPS, a French company specialising in the management and recycling of industrial waste, is now signed. Formal launch of EQTEC business in France. [SP=0.8 Cap=69m]
AFC Energy (AFC) UK construction co Keltbray to lease an initial zero emission Hybrid Fuel Cell power generator as a showcase of how the construction industry can decarbonise. Deployment expected end Q2. [SP=36.7 Cap=270m]
In line: MORE
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Rough & ready regulatory roundup
Cake Box (CBOX) Trading in line. CFO scarpers. He is thanked. [SP=200 Cap=80m]
Live Company (LVCG) £0.225m placing at 5p, a 2% premium, for a video production division, further expansion of the KPOP-FLEX concept and additional working capital. Over 18k tickets for KPOP.FLEX festival. [SP=4.9 Cap=8m]
EQTEC (EQT) collaboration agreement wityh SEPS, a French company specialising in the management and recycling of industrial waste, is now signed. Formal launch of EQTEC business in France. [SP=0.8 Cap=69m]
AFC Energy (AFC) UK construction co Keltbray to lease an initial zero emission Hybrid Fuel Cell power generator as a showcase of how the construction industry can decarbonise. Deployment expected end Q2. [SP=36.7 Cap=270m]
In line: MORE
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 15-Mar-22
Absolutely Fatuous
Chill Brands (CHLL) clarifies reason for restating previous rev figs. Its master distributor (and a substantial shareholder) Ox didn't pay its the outstanding balance because the dog ate its homework. The balance owed will be paid via instalments no later than 1 May 2023. [SP=4.99 Cap=10m]
Microsaic Systems (MSYS) a 'Strategic Update' doesn't have much. "The Company is making progress in transforming from a proprietary equipment-only sales model, to a partner-based business model that adds contract micro-engineering design, build and commission of client equipment as a new revenue source. In addition, medical, environmental and bio-processing test services are to be carried out on Microsaic's own mass spectrometry equipment for external clients..." [SP=0.11 Cap=6m]
Gattaca (GATC) CEO leaves end March. He is thanked. [SP=79.02 Cap=26m]
Active Energy (AEG) gets Forest Stewardship Council certificate, a basic market prerequisite for many of AEG's target markets, for CoalSwitch fuel. [SP=0.13 Cap=7m]
Mobile Streams (MOS) £1.2m placing at 0.3p, a 25% discount, to create a JV with Gfinity and keep the lights on. Also a taken Broker Option for plebs. [SP=0.4 Cap=10m]
ECO Animal Health (EAH) guides FY(Mar) rev and margin in line but 15% to 20% below mkt expectations due to higher R&D spend though it confuses by saying it was "maintained at the budgeted rate". [SP=151 Cap=102m]
ValiRx (VAL) project updates. Also "assessing options to acquire capabilities and infrastructure to create a more efficient and effective translational drug development service" instead of out-sourcing. [SP=21.15 Cap=14m]
Wickes (WIX) prelims delayed to 25 March because auditors want more time. Co continues to expect adjusted pretax £83m+. [SP=175 Cap=454m]
Hargreaves Services (HSP) German JV contribution in H2 will now be >H1 due to high commodity prices. "Future profitability from HRMS is expected to be at least 30% greater than current market expectations, even if current levels of commodity pricing are not sustained." Rest of group in line. [SP=478 Cap=155m]
Ocean Outdoor (OOUT) named preferred bidder for exisitng advertising contract for BFI IMAX. Worth £25m over 5 yrs. [SP=9.71 Cap=498m]
Wilmington (WIL) guides FY22 profit at least 10% above market expectations of £18m because the Group's major face-to-face event in the US - Rise National - has taken place. [SP=250 Cap=219m]
REDD guides FY(Apr) U/L pretax £150m, comfortably ahead of consensus of £133.9m. £30m bayback. [SP=NA Cap=NA]
DFS Furniture (DFS) H1(Dec) rev down 2% but up 15% on H1'20. U/L EPS 6.9p (23.5p). (H1'20: 6p). Special div 10p + £25m buyback. "Our expectations for total profits across FY22 and FY23 remain unchanged." [SP=197.6 Cap=511m]
In line: TRX, VINO
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Absolutely Fatuous
Chill Brands (CHLL) clarifies reason for restating previous rev figs. Its master distributor (and a substantial shareholder) Ox didn't pay its the outstanding balance because the dog ate its homework. The balance owed will be paid via instalments no later than 1 May 2023. [SP=4.99 Cap=10m]
Microsaic Systems (MSYS) a 'Strategic Update' doesn't have much. "The Company is making progress in transforming from a proprietary equipment-only sales model, to a partner-based business model that adds contract micro-engineering design, build and commission of client equipment as a new revenue source. In addition, medical, environmental and bio-processing test services are to be carried out on Microsaic's own mass spectrometry equipment for external clients..." [SP=0.11 Cap=6m]
Gattaca (GATC) CEO leaves end March. He is thanked. [SP=79.02 Cap=26m]
Active Energy (AEG) gets Forest Stewardship Council certificate, a basic market prerequisite for many of AEG's target markets, for CoalSwitch fuel. [SP=0.13 Cap=7m]
Mobile Streams (MOS) £1.2m placing at 0.3p, a 25% discount, to create a JV with Gfinity and keep the lights on. Also a taken Broker Option for plebs. [SP=0.4 Cap=10m]
ECO Animal Health (EAH) guides FY(Mar) rev and margin in line but 15% to 20% below mkt expectations due to higher R&D spend though it confuses by saying it was "maintained at the budgeted rate". [SP=151 Cap=102m]
ValiRx (VAL) project updates. Also "assessing options to acquire capabilities and infrastructure to create a more efficient and effective translational drug development service" instead of out-sourcing. [SP=21.15 Cap=14m]
Wickes (WIX) prelims delayed to 25 March because auditors want more time. Co continues to expect adjusted pretax £83m+. [SP=175 Cap=454m]
Hargreaves Services (HSP) German JV contribution in H2 will now be >H1 due to high commodity prices. "Future profitability from HRMS is expected to be at least 30% greater than current market expectations, even if current levels of commodity pricing are not sustained." Rest of group in line. [SP=478 Cap=155m]
Ocean Outdoor (OOUT) named preferred bidder for exisitng advertising contract for BFI IMAX. Worth £25m over 5 yrs. [SP=9.71 Cap=498m]
Wilmington (WIL) guides FY22 profit at least 10% above market expectations of £18m because the Group's major face-to-face event in the US - Rise National - has taken place. [SP=250 Cap=219m]
REDD guides FY(Apr) U/L pretax £150m, comfortably ahead of consensus of £133.9m. £30m bayback. [SP=NA Cap=NA]
DFS Furniture (DFS) H1(Dec) rev down 2% but up 15% on H1'20. U/L EPS 6.9p (23.5p). (H1'20: 6p). Special div 10p + £25m buyback. "Our expectations for total profits across FY22 and FY23 remain unchanged." [SP=197.6 Cap=511m]
In line: TRX, VINO
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 16-Mar-22
Amputating AM verbosity
SEEEN (SEEN) CEO resigns, becomes non-board. He is thanked . Replaced with 2 co-CEOs. Cessation of YouTube advertising in Russia has hit MCN revenue but little impact on profitability. [SP=16 Cap=8m]
Kooth (KOO) wins contract worth over £1m PA. [SP=248.3 Cap=82m]
IDOX (IDOX) AGM stmt. Sounds in line. [SP=62.2 Cap=277m]
Angling Direct (ANG) European distribution centre is now fully operational. [SP=49 Cap=38m]
Genflow Biosciences (GENF) wins grant for up to €3.375m. [SP=10.25 Cap=NA]
Avacta (AVCT) sells veterinary division for £0.9m + £1.4m earn-out. Last FY op loss £0.3m. [SP=55.05 Cap=140m]
Gym (GYM) FY(Dec) in line. Membership up 15% in first 2 moths of FY22. "Our pace of change is accelerating through the launch of a new technology platform and a brand transformation..." [SP=206 Cap=366m]
Restaurant (RTN) FY(Jan) slight adj EBITDA beat. Current trading strong, outperforming the market. [SP=69.7 Cap=533m]
Science Group (SAG) FY(Dec) rev up 10%, adj op profit up 49%, both ahead of upgraded expectations. Outlook - 'well positioned'. [SP=380 Cap=173m]
In line: EAAS, CAU, EYE
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Amputating AM verbosity
SEEEN (SEEN) CEO resigns, becomes non-board. He is thanked . Replaced with 2 co-CEOs. Cessation of YouTube advertising in Russia has hit MCN revenue but little impact on profitability. [SP=16 Cap=8m]
Kooth (KOO) wins contract worth over £1m PA. [SP=248.3 Cap=82m]
IDOX (IDOX) AGM stmt. Sounds in line. [SP=62.2 Cap=277m]
Angling Direct (ANG) European distribution centre is now fully operational. [SP=49 Cap=38m]
Genflow Biosciences (GENF) wins grant for up to €3.375m. [SP=10.25 Cap=NA]
Avacta (AVCT) sells veterinary division for £0.9m + £1.4m earn-out. Last FY op loss £0.3m. [SP=55.05 Cap=140m]
Gym (GYM) FY(Dec) in line. Membership up 15% in first 2 moths of FY22. "Our pace of change is accelerating through the launch of a new technology platform and a brand transformation..." [SP=206 Cap=366m]
Restaurant (RTN) FY(Jan) slight adj EBITDA beat. Current trading strong, outperforming the market. [SP=69.7 Cap=533m]
Science Group (SAG) FY(Dec) rev up 10%, adj op profit up 49%, both ahead of upgraded expectations. Outlook - 'well positioned'. [SP=380 Cap=173m]
In line: EAAS, CAU, EYE
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 17-Mar-22
Scrubbing out the lavatories of filthy lucre
Deepverge (DVRG) buys engineering services company Glanaco for £1.1m in cash and shares. Allows co to assemble MicrotoxPD in-house. Also £25m loan at 1% pcm. Co will increase the genome sequencing footprint at its North America. [SP=12.51 Cap=27m]
Nanoco (NANO) guides FY(July) rev above FY21 (£2.1m) after contract win. [SP=18.4 Cap=57m]
Avingtrans (AVG) £6m contract win plus 'multi-million dollar' contracts to support the ITER magnetic fusion reactor project. [SP=410 Cap=132m]
4GLOBAL (4GBL) guides FY(Mar) rev in line and adj EBIT and EBITDA expected to be significantly ahead of expectations which are rev £3.6m, adj EBIT £316k and adj EBITDA £325k. Contract wins. [SP=87.41 Cap=NA]
Zinc Media (ZIN) wins 2yr BBC commission worth £2.75m. [SP=78 Cap=13m]
Autins (AUTG) AGM stmt: "H1 FY22 remain similar to H2 FY21 due to the continued impact of semiconductor shortages. The industry had previously forecast an improvement in semiconductor supply in the second half of calendar year 2022, but the war in Ukraine adds to the overall uncertainty and timing of the recovery." [SP=18 Cap=11m]
Synairgen (SNG) gets worse as US halts Phase 2/3 ACTIV-2 covid trial which included the assessment of SNG001. It's "due to the significant shift in the nature of the pandemic which would necessitate a substantial modification of the study design not feasible in this multiple treatment-arm, platform trial". Discussions to try to identify a trial to continue the evaluation of SNG001. Co expects to receive the Phase 2 data from ACTIV-2 in H1. Co prev asked to pause activities to prepare clinical supplies for ACTIV-2. [SP=26 Cap=52m]
Go-ahead (GOG) £23.5m fine for 'good faith contraventions of LSER franchise agreements'. Co failed to pay back more than £25m of taxpayer funding. Had made provision of £30m. [SP=618.05 Cap=267m]
Ten Lifestyle Group (TENG) significant commission from an exisitng global financial services client. Boosts Extra Large contract by the equivalent of a Medium contract (£0.25-2m) over the next 12 months. [SP=84.2 Cap=71m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Scrubbing out the lavatories of filthy lucre
Deepverge (DVRG) buys engineering services company Glanaco for £1.1m in cash and shares. Allows co to assemble MicrotoxPD in-house. Also £25m loan at 1% pcm. Co will increase the genome sequencing footprint at its North America. [SP=12.51 Cap=27m]
Nanoco (NANO) guides FY(July) rev above FY21 (£2.1m) after contract win. [SP=18.4 Cap=57m]
Avingtrans (AVG) £6m contract win plus 'multi-million dollar' contracts to support the ITER magnetic fusion reactor project. [SP=410 Cap=132m]
4GLOBAL (4GBL) guides FY(Mar) rev in line and adj EBIT and EBITDA expected to be significantly ahead of expectations which are rev £3.6m, adj EBIT £316k and adj EBITDA £325k. Contract wins. [SP=87.41 Cap=NA]
Zinc Media (ZIN) wins 2yr BBC commission worth £2.75m. [SP=78 Cap=13m]
Autins (AUTG) AGM stmt: "H1 FY22 remain similar to H2 FY21 due to the continued impact of semiconductor shortages. The industry had previously forecast an improvement in semiconductor supply in the second half of calendar year 2022, but the war in Ukraine adds to the overall uncertainty and timing of the recovery." [SP=18 Cap=11m]
Synairgen (SNG) gets worse as US halts Phase 2/3 ACTIV-2 covid trial which included the assessment of SNG001. It's "due to the significant shift in the nature of the pandemic which would necessitate a substantial modification of the study design not feasible in this multiple treatment-arm, platform trial". Discussions to try to identify a trial to continue the evaluation of SNG001. Co expects to receive the Phase 2 data from ACTIV-2 in H1. Co prev asked to pause activities to prepare clinical supplies for ACTIV-2. [SP=26 Cap=52m]
Go-ahead (GOG) £23.5m fine for 'good faith contraventions of LSER franchise agreements'. Co failed to pay back more than £25m of taxpayer funding. Had made provision of £30m. [SP=618.05 Cap=267m]
Ten Lifestyle Group (TENG) significant commission from an exisitng global financial services client. Boosts Extra Large contract by the equivalent of a Medium contract (£0.25-2m) over the next 12 months. [SP=84.2 Cap=71m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 23-Mar-22
I love the smell of P&L in the morning
Renewi (RWI) guides FY(Mar) ahead of expectations (whose?). "Ongoing high recyclate prices and good cost control more than offsetting volumes that continued to be adversely affected by Covid restrictions" [SP=702 Cap=562m]
4D pharma (DDDD) Part B of study of MRx0518 in combination with MSD's anti-PD-1 therapy (in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment completion. "Another important step forward for MRx0518 and the increasing importance of the microbiome in cancer treatment." [SP=45.16 Cap=81m]
CIP Merchant Capital (CIP) board unanimously and unequivocally rejects CFE's Final Offer of 60p. [SP=63.25 Cap=35m]
ValiRx (VAL) sub-license of VAL201 to TheoremRx delayed due to lack of funds. "Upon successful completion of the financing by TheoremRx, the first payments to ValiRx under the sub-license are anticipated on or before end-June." [SP=26.33 Cap=17m]
WANdisco (WAND) wins $1.5m contract win with a global telco. [SP=334 Cap=200m]
Pennant (PEN) £8.8m 3 yr contract for the Major Programme has now been formally awarded to Pennant by Boeing. ALos 2 other wins worth c.$2.3m [SP=35.64 Cap=13m]
James Cropper (CRPR) guides FY(Mar) rev up 30%, ahead of market expectations but adj pretax £3.5m cf £4.9m expected due to high gas prices hitting profit at paper division. [SP=1277 Cap=122m]
Arecor Therapeutics (AREC) gets US patent for novel formulations of the Group's proprietary insulin products, AT247 and AT278. [SP=346 Cap=96m]
Futura Medical (FUM) grants exclusive rights to commercialise MED3000 in South Korea. Gets initial upfront payment and an agreed price for MED3000. Did FUM have to beat off stiff competition? [SP=25 Cap=72m]
4basebio (4BB) adds to its synthetic DNA product offering with opDNA and oeDNA. No idea if this is a significant addition. [SP=530 Cap=65m]
In line: ABDP, QTX
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
I love the smell of P&L in the morning
Renewi (RWI) guides FY(Mar) ahead of expectations (whose?). "Ongoing high recyclate prices and good cost control more than offsetting volumes that continued to be adversely affected by Covid restrictions" [SP=702 Cap=562m]
4D pharma (DDDD) Part B of study of MRx0518 in combination with MSD's anti-PD-1 therapy (in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment completion. "Another important step forward for MRx0518 and the increasing importance of the microbiome in cancer treatment." [SP=45.16 Cap=81m]
CIP Merchant Capital (CIP) board unanimously and unequivocally rejects CFE's Final Offer of 60p. [SP=63.25 Cap=35m]
ValiRx (VAL) sub-license of VAL201 to TheoremRx delayed due to lack of funds. "Upon successful completion of the financing by TheoremRx, the first payments to ValiRx under the sub-license are anticipated on or before end-June." [SP=26.33 Cap=17m]
WANdisco (WAND) wins $1.5m contract win with a global telco. [SP=334 Cap=200m]
Pennant (PEN) £8.8m 3 yr contract for the Major Programme has now been formally awarded to Pennant by Boeing. ALos 2 other wins worth c.$2.3m [SP=35.64 Cap=13m]
James Cropper (CRPR) guides FY(Mar) rev up 30%, ahead of market expectations but adj pretax £3.5m cf £4.9m expected due to high gas prices hitting profit at paper division. [SP=1277 Cap=122m]
Arecor Therapeutics (AREC) gets US patent for novel formulations of the Group's proprietary insulin products, AT247 and AT278. [SP=346 Cap=96m]
Futura Medical (FUM) grants exclusive rights to commercialise MED3000 in South Korea. Gets initial upfront payment and an agreed price for MED3000. Did FUM have to beat off stiff competition? [SP=25 Cap=72m]
4basebio (4BB) adds to its synthetic DNA product offering with opDNA and oeDNA. No idea if this is a significant addition. [SP=530 Cap=65m]
In line: ABDP, QTX
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 24-Mar-22
£100m work of friction
McColl's (MCLS) CEO scarpers from the cash-stapped retailer. He is thanked. [SP=2.05 Cap=6m]
XP Power (XPP) loses US case to Comet re trade secret misappropriation. $40m awarded. Co prev asserted there was no merit to the lawsuit. [SP=3640 Cap=715m]
Tungsten (TUNG) 42p rec offer made at last. [SP=38.7 Cap=49m]
Surface Transforms (SCE) 5 yr £100m replaces £27.5m 3 yr contact from OEM 8 (Tesla?). [SP=41.5 Cap=81m]
GETECH (GTC) wins contracts in mining sector, worth £110k initially. [SP=28 Cap=19m]
React (REAT) AGM stmt. Positive, sounds in line. [SP=1.9 Cap=10m]
Poolbeg Pharma (POLB) deal with CytoReason, a leading company developing computational disease models for efficient drug discovery and development, to provide AI analysis of Poolbeg's influenza disease progression data derived from human challenge study samples. "This will enable a deep understanding of the mechanism of influenza infection and recovery and, as a result, help identify novel drug targets for the disease." [SP=5.5 Cap=NA]
STM (STM) delays finals because additional time needed to finalise the audit. Operating in line. [SP=28.7 Cap=17m]
Beeks Financial Cloud (BKS) £4.4m 5 yr contract from a new European Tier 1 client. [SP=147 Cap=83m]
Velocys (VLS) as expected, sells 100% interest in Rula Developments. Gets £9.75m. Rula Developments. owns the site for the proposed Altalto waste-to-sustainable-fuel project, which is being developed in collaboration with British Airways. A call option to buy to back and the buyer a right of first refusal to invest up to £100m in the project. [SP=5.8 Cap=81m]
Braemar Shipping Service (BMS) guides FY(Feb) U/L op profit slightly above market expectations of £9.8m. 4p final div. [SP=237.5 Cap=76m]
Animalcare (ANCR) buys global exclusive licence from Orthros Medical for two preclinical VHH antibody candidates, initially addressing canine osteoarthritis. Also R&D agreement to add further projects to the licence agreement. Co pays €500k and will fund some early research activities. [SP=335 Cap=201m]
MTI Wireless Edge (MWE) $0.5m contract to monitor and partially control over 30 fountains in Israel. [SP=63 Cap=56m]
In line: GAW, AOM
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
£100m work of friction
McColl's (MCLS) CEO scarpers from the cash-stapped retailer. He is thanked. [SP=2.05 Cap=6m]
XP Power (XPP) loses US case to Comet re trade secret misappropriation. $40m awarded. Co prev asserted there was no merit to the lawsuit. [SP=3640 Cap=715m]
Tungsten (TUNG) 42p rec offer made at last. [SP=38.7 Cap=49m]
Surface Transforms (SCE) 5 yr £100m replaces £27.5m 3 yr contact from OEM 8 (Tesla?). [SP=41.5 Cap=81m]
GETECH (GTC) wins contracts in mining sector, worth £110k initially. [SP=28 Cap=19m]
React (REAT) AGM stmt. Positive, sounds in line. [SP=1.9 Cap=10m]
Poolbeg Pharma (POLB) deal with CytoReason, a leading company developing computational disease models for efficient drug discovery and development, to provide AI analysis of Poolbeg's influenza disease progression data derived from human challenge study samples. "This will enable a deep understanding of the mechanism of influenza infection and recovery and, as a result, help identify novel drug targets for the disease." [SP=5.5 Cap=NA]
STM (STM) delays finals because additional time needed to finalise the audit. Operating in line. [SP=28.7 Cap=17m]
Beeks Financial Cloud (BKS) £4.4m 5 yr contract from a new European Tier 1 client. [SP=147 Cap=83m]
Velocys (VLS) as expected, sells 100% interest in Rula Developments. Gets £9.75m. Rula Developments. owns the site for the proposed Altalto waste-to-sustainable-fuel project, which is being developed in collaboration with British Airways. A call option to buy to back and the buyer a right of first refusal to invest up to £100m in the project. [SP=5.8 Cap=81m]
Braemar Shipping Service (BMS) guides FY(Feb) U/L op profit slightly above market expectations of £9.8m. 4p final div. [SP=237.5 Cap=76m]
Animalcare (ANCR) buys global exclusive licence from Orthros Medical for two preclinical VHH antibody candidates, initially addressing canine osteoarthritis. Also R&D agreement to add further projects to the licence agreement. Co pays €500k and will fund some early research activities. [SP=335 Cap=201m]
MTI Wireless Edge (MWE) $0.5m contract to monitor and partially control over 30 fountains in Israel. [SP=63 Cap=56m]
In line: GAW, AOM
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 25-Mar-22
A financial finger in the air
Sabien Technology (SNT) £264k conttact from UK gov't. [SP=20 Cap=3m]
CyanConnode (CYAN) yet another placing. £2m at 14p, a 2% discount, to keep the lights on. Shares in issue have increased 2000x since 2005, adjusted for the 200:1 consolidation. [SP=14 Cap=31m]
Ondo InsurTech (ONDO) name change from Spinnaker Acquisitions following RTO. [SP=9 Cap=2m]
Hibernia Reit (HBRN) rec offer of €1.634 including a 3.4 cent dividend. [SP=98.1 Cap=942m]
Go-Ahead (GOG) will continue operating Thameslink, Southern and Great Northern rail to 2025 on a management contract. [SP=700.7 Cap=303m]
Open Orphan (ORPH) wins £5m respiratory syncytial virus human challenge study contract. [SP=13.28 Cap=89m]
Journeo (JNEO) 3 yr renewal of the exclusive distribution agreement with Safety Tech, a subsidiary of Vision Systems France. Will also supply Journeo CMS to specialist vehicle providers and to bus and coach operators throughout Sweden. No £££. [SP=100 Cap=9m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
A financial finger in the air
Sabien Technology (SNT) £264k conttact from UK gov't. [SP=20 Cap=3m]
CyanConnode (CYAN) yet another placing. £2m at 14p, a 2% discount, to keep the lights on. Shares in issue have increased 2000x since 2005, adjusted for the 200:1 consolidation. [SP=14 Cap=31m]
Ondo InsurTech (ONDO) name change from Spinnaker Acquisitions following RTO. [SP=9 Cap=2m]
Hibernia Reit (HBRN) rec offer of €1.634 including a 3.4 cent dividend. [SP=98.1 Cap=942m]
Go-Ahead (GOG) will continue operating Thameslink, Southern and Great Northern rail to 2025 on a management contract. [SP=700.7 Cap=303m]
Open Orphan (ORPH) wins £5m respiratory syncytial virus human challenge study contract. [SP=13.28 Cap=89m]
Journeo (JNEO) 3 yr renewal of the exclusive distribution agreement with Safety Tech, a subsidiary of Vision Systems France. Will also supply Journeo CMS to specialist vehicle providers and to bus and coach operators throughout Sweden. No £££. [SP=100 Cap=9m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 29-Mar-22
Steaming the PR wallpaper off smallcaps
Gore Street Energy Storage Fund (GSF) £75m placing at 110p, a 6% discount. [SP=115 Cap=397m]
Driver (DRV) warns H1 pretax only £300-500k (£1m) due to a problematic loss-making contract in the APAC region and an unexpected drop in revenues in the Middle East region. WIll cuts costs in those regions by £1m PA. CFO scarpers. He is not thanked. [SP=38.5 Cap=21m]
Toople (TOOP) £300k convertible at 10% PA from investors and shareholders to keep the lights on. Board is also exploring EBITDA enhancing M&A opportunities. [SP=0.03 Cap=1m]
Deepverge (DVRG) MoU with Abingdon Health leading to a Commercial Agreement for development and manufacture of a range of Lateral Flow Tests for the Modern Water, Labskin and Skin Trust Medical divisions. [SP=13.5 Cap=30m]
R.E.A. Holding (RE.) Indonesian government has published a change to the export levy structure. Result is an increase of $200 per tonne from Apr. [SP=169 Cap=74m]
McKay Securities (MCKS) Slate Asset Management considering competing offer for co. [SP=284 Cap=256m]
Mulberry (MUL) guides FY(Apr) rev and profit moderately ahead of expectations (whose?). [SP=300 Cap=180m]
Silver Bullet Data Services (SBDS) four contract wins. No £££. [SP=165.15 Cap=22m]
James Latham (LTHM) guides FY(Mar) rev over £370m (£250m). "Cost prices have continued to rise throughout the year which is a major driver of the increase in revenues, and there are no signs currently of price weaknesses. Volume growth has slowed and gross margins percentages are now returning to more normal levels, as expected. Supply chain issues have continued, with shipment delays and congestion at the ports, and this has been exacerbated by the events in Ukraine and its effect on Russian ships and ports. We are still maintaining higher than normal inventory levels." Overheads up. [SP=1282 Cap=256m]
NAHL (NAH) FY(Dec) poor but in line. Outlook: Personal Injury enquiry volumes in the first two months up 42%. Critical Care, Expert Witness and INA reports issued up 7-8%. Expert Witness and INA report instructions were ahead by 7% and 28% respectively. [SP=44.1 Cap=20m]
Mission Group (TMG) FY(Dec) adj pretax £7.5m, ahead of market expectations. FY22 in line. [SP=54.5 Cap=50m]
Skinbiotherapeutics (SBTX) H1 rev materially below budget. Guides FY also materially below exp but "without having implemented its full marketing campaign, it is not possible to predict at this time the quantum of the impact on sales". [SP=45.98 Cap=72m]
XLMedia (XLM) FY(Dec) rev up 21%. Has material uncertainty going concern stmt. FY22 in line. [SP=28.4 Cap=75m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Steaming the PR wallpaper off smallcaps
Gore Street Energy Storage Fund (GSF) £75m placing at 110p, a 6% discount. [SP=115 Cap=397m]
Driver (DRV) warns H1 pretax only £300-500k (£1m) due to a problematic loss-making contract in the APAC region and an unexpected drop in revenues in the Middle East region. WIll cuts costs in those regions by £1m PA. CFO scarpers. He is not thanked. [SP=38.5 Cap=21m]
Toople (TOOP) £300k convertible at 10% PA from investors and shareholders to keep the lights on. Board is also exploring EBITDA enhancing M&A opportunities. [SP=0.03 Cap=1m]
Deepverge (DVRG) MoU with Abingdon Health leading to a Commercial Agreement for development and manufacture of a range of Lateral Flow Tests for the Modern Water, Labskin and Skin Trust Medical divisions. [SP=13.5 Cap=30m]
R.E.A. Holding (RE.) Indonesian government has published a change to the export levy structure. Result is an increase of $200 per tonne from Apr. [SP=169 Cap=74m]
McKay Securities (MCKS) Slate Asset Management considering competing offer for co. [SP=284 Cap=256m]
Mulberry (MUL) guides FY(Apr) rev and profit moderately ahead of expectations (whose?). [SP=300 Cap=180m]
Silver Bullet Data Services (SBDS) four contract wins. No £££. [SP=165.15 Cap=22m]
James Latham (LTHM) guides FY(Mar) rev over £370m (£250m). "Cost prices have continued to rise throughout the year which is a major driver of the increase in revenues, and there are no signs currently of price weaknesses. Volume growth has slowed and gross margins percentages are now returning to more normal levels, as expected. Supply chain issues have continued, with shipment delays and congestion at the ports, and this has been exacerbated by the events in Ukraine and its effect on Russian ships and ports. We are still maintaining higher than normal inventory levels." Overheads up. [SP=1282 Cap=256m]
NAHL (NAH) FY(Dec) poor but in line. Outlook: Personal Injury enquiry volumes in the first two months up 42%. Critical Care, Expert Witness and INA reports issued up 7-8%. Expert Witness and INA report instructions were ahead by 7% and 28% respectively. [SP=44.1 Cap=20m]
Mission Group (TMG) FY(Dec) adj pretax £7.5m, ahead of market expectations. FY22 in line. [SP=54.5 Cap=50m]
Skinbiotherapeutics (SBTX) H1 rev materially below budget. Guides FY also materially below exp but "without having implemented its full marketing campaign, it is not possible to predict at this time the quantum of the impact on sales". [SP=45.98 Cap=72m]
XLMedia (XLM) FY(Dec) rev up 21%. Has material uncertainty going concern stmt. FY22 in line. [SP=28.4 Cap=75m]
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 30-Mar-22
Rolling up my sleeves for the pregnant cash cows
Ebiquity (EQB) £15m placing at 53p, a 9% discount, to fund acquisition of Media Path Network, a Swedish-based multi-national media consultancy. [SP=NA Cap=NA]
John Menzies (MNZS) rec offer at 608p. [SP=570 Cap=524m]
eEnergy (EAAS) partnership signed with EO Charging to create the UK's largest public sector charging network, launched via new "eCharge" brand. [SP=10.24 Cap=35m]
Bloomsbury Publishing (BMY) guides FY(Feb) rev comfortably ahead and profit materially ahead of upgraded market expectations. F/C rev £212.5m and profit before taxation and highlighted items £22.3m. [SP=365 Cap=298m]
Gaming Realms (GMR) has gone live with Loto-Québec. [SP=29.5 Cap=86m]
Belluscura (BELL) signs manufacturing Master Supply Agreement with InnoMax Medical Technology, to manufacture the X-PLO2R portable oxygen concentrator in China. It will more than double manufacturing capacity next year. [SP=99 Cap=113m]
Diurnal (DNL) distribution agreement with Vector Pharma, a leading full-service distributor, for Alkindi across the Middle East and North Africa regions. Alkindi is the first licensed preparation of hydrocortisone designed for use in children suffering from adrenal insufficiency. [SP=16 Cap=27m]
Strix (KETL) FY(Dec) rev up 25%, pretax up 4%, modestly ahead of consensus. Outlook: "implemented price increases on some of its legacy products...and will also be implementing further increases across the wider range with effect from 1 May, which alongside a range of other efficiency measures and foreign exchange rate and commodity hedging arrangements will help to minimise the impact of any cost inflation...there are a number of headwinds which continue to persist including increases in commodity prices, freight cost inflation, supply chainand adverse foreign exchange rates." [SP=240.46 Cap=497m]
Symphony Environmental Technologies (SYM) FY(Dec) rev £9.2m cf guidance £9.8m. Op loss £1.5m cf £0.8m guided. Outlook - trade has started to improve following a slow start. [SP=15.05 Cap=27m]
In line: SEE
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Rolling up my sleeves for the pregnant cash cows
Ebiquity (EQB) £15m placing at 53p, a 9% discount, to fund acquisition of Media Path Network, a Swedish-based multi-national media consultancy. [SP=NA Cap=NA]
John Menzies (MNZS) rec offer at 608p. [SP=570 Cap=524m]
eEnergy (EAAS) partnership signed with EO Charging to create the UK's largest public sector charging network, launched via new "eCharge" brand. [SP=10.24 Cap=35m]
Bloomsbury Publishing (BMY) guides FY(Feb) rev comfortably ahead and profit materially ahead of upgraded market expectations. F/C rev £212.5m and profit before taxation and highlighted items £22.3m. [SP=365 Cap=298m]
Gaming Realms (GMR) has gone live with Loto-Québec. [SP=29.5 Cap=86m]
Belluscura (BELL) signs manufacturing Master Supply Agreement with InnoMax Medical Technology, to manufacture the X-PLO2R portable oxygen concentrator in China. It will more than double manufacturing capacity next year. [SP=99 Cap=113m]
Diurnal (DNL) distribution agreement with Vector Pharma, a leading full-service distributor, for Alkindi across the Middle East and North Africa regions. Alkindi is the first licensed preparation of hydrocortisone designed for use in children suffering from adrenal insufficiency. [SP=16 Cap=27m]
Strix (KETL) FY(Dec) rev up 25%, pretax up 4%, modestly ahead of consensus. Outlook: "implemented price increases on some of its legacy products...and will also be implementing further increases across the wider range with effect from 1 May, which alongside a range of other efficiency measures and foreign exchange rate and commodity hedging arrangements will help to minimise the impact of any cost inflation...there are a number of headwinds which continue to persist including increases in commodity prices, freight cost inflation, supply chainand adverse foreign exchange rates." [SP=240.46 Cap=497m]
Symphony Environmental Technologies (SYM) FY(Dec) rev £9.2m cf guidance £9.8m. Op loss £1.5m cf £0.8m guided. Outlook - trade has started to improve following a slow start. [SP=15.05 Cap=27m]
In line: SEE
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
-
MrContrarian
- Lemon Quarter
- Posts: 1778
- Joined: November 4th, 2016, 2:45 pm
- Has thanked: 43 times
- Been thanked: 1611 times
Re: MrC's Smallcap Sweeps for Mar 2022
Smallcap Sweep. 31-Mar-22
Boring through the boring
Bion (BION) sells its hopeless main operational subsidiary for a Quid, becomes cash shell. £1m placing at 0.3p, an 82% discount to the pre-suspension price. [SP=1.8 Cap=7m]
Agriterra (AGTA) trading. No summary but sounds positive. Outlook: "below average rainfall and the increased price of wheat and oil (due to the ongoing conflict in Ukraine), will reduce the availability of local food and cause a higher demand for the Company's products...Import restrictions on meat from South Africa and the growing demand from Maputo and the oil and gas sectors are likely to drive up demand for the Company's beef." [SP=4.86 Cap=1m]
Brewin Dolphin(BRW) 515p rec offer, a 62% premium. [SP=318 Cap=966m]
Polarean Imaging (POLX) resubmits FDA application for its drug‑device combination product using hyperpolarised Xenon gas to enhance MRI in pulmonary medicine. [SP=52 Cap=109m]
Active Energy (AEG) sells Lumberton Site for $4.65m. Cash will be used for the development of the Company's CoalSwitch production facility at Ashland, Maine. "AEG is seeing unprecedented [ie higher than the previous low level] enquiries for the CoalSwitch product following the independent test results." [SP=0.15 Cap=8m]
Altitude (ALT) guides FY(Mar) rev c. £12m and adj op profit c.£1m, up c. 56% and c. 80% . [SP=34.25 Cap=24m]
WANdisco (WAND) additional $1.2m order from top ten global communications company that placed initial $1.5m order last week. [SP=311.21 Cap=187m]
Feedback (FDBK) the first patient has gone through Bleepa's cloud-based TB screening pathway at the Evangelical Hospital Khariar, India. [SP=0.7 Cap=19m]
NWF (NWF) second upgrade this month! Sees FY(May) significantly ahead of the revised expectations due to fuels business. [SP=222.33 Cap=109m]
Toople (TOOP) AGM stmt: orders particularly strong in March with a material increase in high bandwidth leased line orders which have significantly higher values and greater margin. [SP=0.02 Cap=1m]
M&C Saatchi (SAA) PUSU date pushed back again. [SP=166 Cap=203m]
Xeros Technology (XSG) China lockdowns mean its no longer likely to reach month on month EBITDA profitability and cash breakeven in the first quarter of 2023. Cash at hand £6.2m, "sufficient to fund the delivery of major growth milestones through the remainder of 2022 and into the first quarter of 2023. The Board is actively evaluating several funding options to secure the remaining investment required." [SP=86.75 Cap=21m]
City of London Group (CIN) £100m in lending to SMEs six months after achieving its full banking licence in Sept. Recognise Bank has also generated £95m in deposits. In line? [SP=59.46 Cap=64m]
GYG (GYG) terms agreed on both of the bankrupt Nobiskrug shipyard New Build projects that were suspended in 2021. Russian superyacht ownership is 7-10% of the global market, co's current exposure is in line with these figures. Mitigating with new biz "across the Mediterranean, Northern Europe and the USA and have built a solid pipeline of prospective work, spanning over 185 projects amounting to approximately €200m potential revenue." [SP=31.4 Cap=15m]
In line: PRES
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Boring through the boring
Bion (BION) sells its hopeless main operational subsidiary for a Quid, becomes cash shell. £1m placing at 0.3p, an 82% discount to the pre-suspension price. [SP=1.8 Cap=7m]
Agriterra (AGTA) trading. No summary but sounds positive. Outlook: "below average rainfall and the increased price of wheat and oil (due to the ongoing conflict in Ukraine), will reduce the availability of local food and cause a higher demand for the Company's products...Import restrictions on meat from South Africa and the growing demand from Maputo and the oil and gas sectors are likely to drive up demand for the Company's beef." [SP=4.86 Cap=1m]
Brewin Dolphin(BRW) 515p rec offer, a 62% premium. [SP=318 Cap=966m]
Polarean Imaging (POLX) resubmits FDA application for its drug‑device combination product using hyperpolarised Xenon gas to enhance MRI in pulmonary medicine. [SP=52 Cap=109m]
Active Energy (AEG) sells Lumberton Site for $4.65m. Cash will be used for the development of the Company's CoalSwitch production facility at Ashland, Maine. "AEG is seeing unprecedented [ie higher than the previous low level] enquiries for the CoalSwitch product following the independent test results." [SP=0.15 Cap=8m]
Altitude (ALT) guides FY(Mar) rev c. £12m and adj op profit c.£1m, up c. 56% and c. 80% . [SP=34.25 Cap=24m]
WANdisco (WAND) additional $1.2m order from top ten global communications company that placed initial $1.5m order last week. [SP=311.21 Cap=187m]
Feedback (FDBK) the first patient has gone through Bleepa's cloud-based TB screening pathway at the Evangelical Hospital Khariar, India. [SP=0.7 Cap=19m]
NWF (NWF) second upgrade this month! Sees FY(May) significantly ahead of the revised expectations due to fuels business. [SP=222.33 Cap=109m]
Toople (TOOP) AGM stmt: orders particularly strong in March with a material increase in high bandwidth leased line orders which have significantly higher values and greater margin. [SP=0.02 Cap=1m]
M&C Saatchi (SAA) PUSU date pushed back again. [SP=166 Cap=203m]
Xeros Technology (XSG) China lockdowns mean its no longer likely to reach month on month EBITDA profitability and cash breakeven in the first quarter of 2023. Cash at hand £6.2m, "sufficient to fund the delivery of major growth milestones through the remainder of 2022 and into the first quarter of 2023. The Board is actively evaluating several funding options to secure the remaining investment required." [SP=86.75 Cap=21m]
City of London Group (CIN) £100m in lending to SMEs six months after achieving its full banking licence in Sept. Recognise Bank has also generated £95m in deposits. In line? [SP=59.46 Cap=64m]
GYG (GYG) terms agreed on both of the bankrupt Nobiskrug shipyard New Build projects that were suspended in 2021. Russian superyacht ownership is 7-10% of the global market, co's current exposure is in line with these figures. Mitigating with new biz "across the Mediterranean, Northern Europe and the USA and have built a solid pipeline of prospective work, spanning over 185 projects amounting to approximately €200m potential revenue." [SP=31.4 Cap=15m]
In line: PRES
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Return to “Stocks and Share Dealing Discussions”
Who is online
Users browsing this forum: No registered users and 39 guests